Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

c-Met/HGFR

c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene. The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor.MET is a single pass tyrosine kinase receptor essential for embryonic development, organogenesis and wound healing.

Tepotinib
T61211100598-32-0
Tepotinib (EMD-1214063) is a c-MET tyrosine kinase inhibitor (IC50=3 nM) that is selective, orally active, and ATP-competitive. Tepotinib has antitumor effect and is used in the treatment of non-small cell lung cancer.
  • $43
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Herbacetin
T5S1331527-95-7
1. Herbacetin induces apoptosis in HepG2 cells, by ROS and PI3K Akt pathway. 2. Herbacetin suppresses the HGF-induced motility of human breast cancer MDA-MB-231 cells by inhibiting c-Met and Akt phosphorylation.
  • $39
In Stock
Size
QTY
Capmatinib
T19631029712-80-8
Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.
  • $43
In Stock
Size
QTY
TargetMol | Citations Cited
Cabozantinib
T2586849217-68-1
Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035 1.3 4.6 7 11.3 nM). Cabozantinib exhibits both antitumor and antiangiogenic activity.
  • $39
In Stock
Size
QTY
TargetMol | Citations Cited
Dihexa
T73761401708-83-5
Dihexa (Hexanoyl-Tyr-Ile-Ahx-NH2) is an activator of the hepatocyte growth factor/c-Met (HGF/c-Met) system,it binds to HGF (Kd = 65 pM),and an analog of the peptide angiotensin IV.
  • $63
In Stock
Size
QTY
SGI-7079
T69821239875-86-5
SGI-7079 is a new selective Axl inhibitor. SGI-7079 can be a dose-dependent manner inhibited growth of tumors. It is also a potential therapeutic target for EGFR inhibitor resistance.
  • $35
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Telisotuzumab
T774371781223-80-0
Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.Telisotuzumab has inhibitory effects on c-Met signaling and antitumor activity.
  • $372
In Stock
Size
QTY
Amivantamab
T771102171511-58-1
Amivantamab (JNJ-61186372) is a humanized antibody that recognizes epidermal growth factor receptor (EGFR) and MET proto-oncogene (MET), with anticancer and anti-tumor activities, preventing ligand binding to EGFR and MET and receptor dimerization that inhibits downstream signal transduction. Amivantamab can induce Fc-dependent endocytosis of macrophages and antibody-dependent cytotoxicity of natural killer cells, and can be used to study metastatic non-small cell lung cancer.
  • $289
In Stock
Size
QTY
Bozitinib
T105851440964-89-5
Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability. Bozitinib binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily.
  • $108
In Stock
Size
QTY
Crizotinib
T1661877399-52-5
Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinase inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptors.
  • $46
In Stock
Size
QTY
TargetMol | Citations Cited
PHA-665752
T6128477575-56-7
PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.
  • $59
In Stock
Size
QTY
TargetMol | Citations Cited
Terevalefim
T375961070881-42-3
Terevalefim (ANG-3777) is an hepatocyte growth factor (HGF) mimetic. Terevalefim selectively activates the c-Met receptor.
  • $51
In Stock
Size
QTY
Savolitinib
TQ02101313725-88-0
Savolitinib (Volitinib) (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM 3 nM for c-Met p-Met).
  • $42
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
Ningetinib
TQ00211394820-69-9
Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
  • $42
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
Foretinib
T3113849217-64-7
Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.
  • $33
In Stock
Size
QTY
TargetMol | Citations Cited
BMS-794833
T24191174046-72-0
BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.
  • $35
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Ensartinib hydrochloride
T223242137030-98-7
Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known crizotinib-resistant ALK mutations. It potently inhibits both wild-type ALK and ALK variants (C1156Y, F1174, G1202R, L1196M, S1206R, and T1151 mutants) with in vitro IC50s of <4 nM.
  • $60
In Stock
Size
QTY
BMS-2
T8326888719-03-7
BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.
  • $65
In Stock
Size
QTY
Onartuzumab
T767801133766-06-9
Onartuzumab (MetMAb) is a humanized anti-tyrosine kinase c-MET monovalent monoclonal antibody.Onartuzumab has antitumor activity with inhibitory effects on HGF binding, receptor phosphorylation, and signal transduction.
  • $450
In Stock
Size
QTY
Pamufetinib
T131081190836-34-0
Pamufetinib (TAS-115) is a potent kinase inhibitor targeting VEGFR and the hepatocyte growth factor receptor (c-Met HGFR), with IC50s of 30 nM for rVEGFR2 and 32 nM for rMET, respectively.
  • $46
In Stock
Size
QTY
TargetMol | Inhibitor Sale
RIPK3-IN-1
T635442361139-70-8
RIPK3-IN-1 is a selective and potent RIPK3 inhibitor (IC50: 9.1 nM) that inhibits the activities of c-Met kinase, RIPK1 and RIPK2.RIPK3-IN-1 has potential tumorigenic activity and can be used to study apoptosis.
  • $71
In Stock
Size
QTY
SU11274
T6154658084-23-2
SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.
  • $39
In Stock
Size
QTY
SAR125844
T54671116743-46-4
SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L)
  • $31
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Fosgonimeton acetate
T39507L
Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).
  • $118
In Stock
Size
QTY
TargetMol | Inhibitor Sale
SGX-523
T22931022150-57-7
SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.
  • $44
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
CSF1R-IN-2
T131942271119-26-5
CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).
  • $38
In Stock
Size
QTY
TargetMol | Inhibitor Sale
NVP-TAE 226
T1918761437-28-9
NVP-TAE 226 (TAE226) is a potent FAK inhibitor (IC50: 5.5 nM), exhibiting even greater efficacy against Pyk2 (IC50: 3.5 nM), and is 10- to 100-fold less effective against IGF-1R, InsR, c-Met, and ALK.
  • $41
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
S49076
T32741265965-22-7
S49076 is a novel and potent inhibitor of MET, AXL MER, and FGFR1 2 3, effectively blocking cellular phosphorylation of MET, AXL, and FGFRs.
  • $39
In Stock
Size
QTY
JNJ-38877618
T15617943540-74-7
JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).
  • $34
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Altiratinib
T20541345847-93-9
Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with an HGF antagonist in vitro.
  • $48
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Crizotinib hydrochloride
T83991415560-69-8
Crizotinib hydrochloride (PF-02341066 hydrochloride) is a novel inhibitor of anaplastic lymphoma kinase and c-Met, with IC50 values of 20 nM and 8 nM, respectively.
  • $31
In Stock
Size
QTY
Tivantinib
T6117905854-02-6
Tivantinib (ARQ 197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.
  • $47
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
Cabozantinib S-malate
T17971140909-48-3
Cabozantinib S-malate (XL184) is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity.
  • $40
In Stock
Size
QTY
BMS-754807
T23491001350-96-4
Dual IGF-1R/InsR Inhibitor BMS-754807 is an oral small molecule inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR) tyrosine kinases with potential antineoplastic activity.
  • $45
In Stock
Size
QTY
Golvatinib
T6517928037-13-2
Golvatinib (E-7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity. c-Met VEGFR kinase inhibitor E7050 binds to and inhibits the activities of both c-Met and VEGFR-2, which may inhibit tumor cell growth and survival of tumor cells that overexpress these receptor tyrosine kinases. c-Met and VEGFR-2 are upregulated in a variety of tumor cell types and play important roles in tumor cell growth, migration and angiogenesis.
  • $37
In Stock
Size
QTY
TargetMol | Inhibitor Sale
SCR-1481B1
T53491174161-86-4
SCR-1481B1 (c-Met inhibitor 2) has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor
  • $32
In Stock
Size
QTY
Capmatinib 2HCl.H2O
T88251865733-40-9
Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.
  • $45
In Stock
Size
QTY
Amuvatinib
T2516850879-09-3
Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.
  • $44
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
URMC-099
T60571229582-33-5
URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19/42/14/150 nM, for MLK1/MLK2/MLK3/DLK), and also inhibits LRRK2 activity (IC50: 11 nM).
  • $52
In Stock
Size
QTY
Merestinib
T34551206799-15-6
Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity. Merestinib electively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing the constitutively activated c-Met protein.
  • $38
In Stock
Size
QTY
TargetMol | Inhibitor Sale
BMS 777607
T26991025720-94-8
BMS 777607 (BMS 817378) is a Met-related inhibitor targeting c-Met, Axl, Ron, and Tyro3 with IC50 values of 3.9 nM, 1.1 nM, 1.8 nM, and 4.3 nM, respectively. BMS-777607 has been investigated in basic science research for malignant solid tumors.
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Sale
C-Met inhibitor D9
T67859299405-67-7
C-Met inhibitor D9 is a c-Met kinase inhibitor.
  • $195
In Stock
Size
QTY
AMG-337
T32091173699-31-4
AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337(AMG337) inhibits MET kinase activity (IC50: < 5 nM).
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
BMS817378
T77871174161-69-3
BMS817378 is a potent and selective inhibitor of MET(IC50 : 1.7 nM).
  • $85
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Glumetinib
T54141642581-63-2
Glumetinib (SCC244) is a novel potent and selective inhibitor of c-Met kinase (IC50: 0.42 nM).
  • $50
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Pamufetinib mesylate
T13108L1688673-09-7
Pamufetinib mesylate (TAS-115 mesylate) is a potent vascular endothelial growth factor receptor (VEGFR) antagonist and hepatocyte growth factor receptor (c-Met) inhibitor used in the study of cancer and respiratory diseases.
  • $95
In Stock
Size
QTY
Bacitracin Zinc
T22081405-89-6
Bacitracin Zinc is an antibiotic that interferes with the dephosphorylation of C55-isoprenyl pyrophosphate, interference for inhibition of cleavage of Tyr from Met-enkephalin(IC50=10 μM).
  • $36
In Stock
Size
QTY
(±)-Norcantharidin
T565629745-04-8
(±)-Norcantharidin (Endothall anhydride) is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
  • $37
In Stock
Size
QTY
TargetMol | Inhibitor Sale